RayzeBio

INDIANAPOLIS - RayzeBio, a Bristol Myers Squibb company, plans to invest more than $173 million in its central Indiana operations and build a new facility in Whitestown. The company announced plans to establish an approximately 450,000-square-foot facilit

The post A Phase 1, First-in-human, Dose-escalation and -expansion Study Of RYZ401, A Novel Radiopharmaceutical Therapy Labeled With Actinium-225, In Patients With Neuroendocrine Tumors And Other Solid Tumors Expressing Somatostatin Receptors appeared fir

The post A phase 1/1b Study of the Theranostic Pair RYZ811 (diagnostic) And RYZ801 (therapeutic) In Patients With Glypican-3-positive (gpc3+) Previously Treated, Unresectable Hepatocellular Carcinoma appeared first on RayzeBio.

The post RYZ101 ( 225 Ac-DOTATATE) + carboplatin + etoposide + atezolizumab in somatostatin receptor-expressing extensive-stage SCLC appeared first on RayzeBio.

The post RYZ101 ( 225 Ac-DOTATATE) pembrolizumab in estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced and unresectable or metastatic breast cancer progressing after prior therapy: the Phase 1b/2 TRACY-1 study

The post 68 GaGa-RAYZ-8009: A Glypican-3-Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging-A First-in-Human Case Series appeared first on RayzeBio.

The post RYZ101 ( 225 Ac-DOTATATE) + carboplatin + etoposide + atezolizumab in somatostatin receptor expressing extensive-stage small-cell lung cancer appeared first on RayzeBio.

The post Phase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: Safety and efficacy findings appeared first on RayzeBio.

San Diego-based Candid Therapeutics, helmed by former RayzeBio CEO Ken Song, will test two promising autoimmune drug candidates.

The post Phase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analog therapy: Safety and efficacy findings appeared first on RayzeBio.